Samsung Biologics Signs $262M Biologics Manufacturing Deal With Undisclosed European Pharma Company

Samsung Biologics disclosed a new contract manufacturing agreement worth approximately $262 million (350.8 billion won) with an undisclosed European pharmaceutical company, in a regulatory filing.¹ The agreement runs through December 31, 2033, with production to take place at Samsung Biologics' Songdo, South Korea, manufacturing site.¹ The client's identity and the product being manufactured were not disclosed, citing business confidentiality provisions, though Samsung Biologics noted the confidentiality period is subject to change.¹ The deal brings the company's cumulative contract value since its founding to more than $21.9 billion.²

How does this deal fit into Samsung Biologics' broader growth strategy?

This is not the first large, confidentially-structured European manufacturing agreement Samsung Biologics has disclosed. In January 2025, the company signed a similarly structured contract worth more than $1.4 billion with an undisclosed Europe-based pharmaceutical company, also for production at Songdo and running through December 2030.³ Samsung Biologics currently operates 845 kL of global manufacturing capacity, with 785 kL concentrated across its Bio Campus I and II sites in South Korea and 60 kL at its Rockville, Maryland facility.⁴ Samsung Biologics acquired the Rockville site from GSK in a transaction announced in December 2025 and expected to close by the end of Q1 2026, marking the company's first planned US manufacturing presence; the reported capacity totals suggest that transaction has since closed, though I have not independently confirmed a closing date beyond that expectation.⁴

The company has also been diversifying beyond its traditional antibody manufacturing base. In July 2026, Samsung Biologics announced an all-cash offer worth approximately $1.8 billion to acquire PolyPeptide Group, a Swiss CDMO specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients, a move intended to expand its capabilities into peptide therapeutics, including GLP-1 medicines.⁵ Samsung Biologics has also built out dedicated antibody-drug conjugate (ADC) manufacturing capabilities, with an ADC-specific facility beginning operations in March 2025.⁶

Why does Samsung Biologics' shift toward complex molecules matter?

Samsung Biologics has pointed to a broader shift in its customer pipeline toward more structurally complex biologics. Kasper Øland, the company's vice president of sales execution, told BioPharm International in an interview at the 2026 BIO International Convention that complex molecules — including bispecific and multispecific antibodies and ADCs — now represent more than 55% of Samsung Biologics' customer pipeline, surpassing conventional monoclonal antibodies as the dominant modality.⁷ Øland described the shift in CDMO expectations that comes with that complexity: "It's about getting started as soon as possible and managing the risks," framing speed-to-market not as a technical mystery but as the result of applying tailored development platforms to the right molecule at the right stage.⁷ He also noted that tighter venture capital funding conditions have compressed IND timelines industry-wide and reduced biotech companies' tolerance for development risk, pushing them to expect CDMOs to function less like vendors and more like an extension of their own operational teams.⁷

What happens next?

Samsung Biologics said demand for long-term manufacturing capacity remains strong across its network, and the company continues to evaluate future capacity investments in line with market demand and evolving client needs.² The PolyPeptide acquisition's tender offer period is expected to run from September 15 through October 12, 2026, with Samsung Biologics aiming to complete the transaction by the end of 2026.⁵

References

1. Samsung Biologics Wins 350.8 Billion Won CMO Deal With European Drugmaker. Seoul Economic Daily. Published September 10, 2026. Accessed September 11, 2026.
2. Kansteiner F. Samsung Bio, Waiting to Break Into Peptides, Nets $262M Manufacturing Deal With Unnamed EU Pharma. Fierce Pharma. Published September 10, 2026. Accessed September 11, 2026.
3. Marisol F. Samsung Biologics Inks More Than $1.4 Billion Manufacturing Deal with European Pharma Company. BioPharm International. Published January 16, 2025. Accessed September 11, 2026.
4. Marisol F. Samsung Biologics Bolsters US Manufacturing Network with GSK Facility Buy. BioPharm International. Published December 22, 2025. Accessed September 11, 2026.
5. Abbott J. Samsung Biologics Offers to Acquire PolyPeptide for $1.8B. BioProcess International. Published July 20, 2026. Accessed September 11, 2026.
6. Mirasol F. Samsung Biologics Partners with LegoChem Biosciences on ADCs. BioPharm International. Published. February 12, 2024. Accessed September 11, 2026.
7. Jacobus N, Øland K, Mirasol F. Samsung Biologics' Kasper Øland Discusses Why Biopharma's Shift to Complex Molecules Is Redefining What Biotech Companies Require From CDMO Partners. BioPharm International. Published July 1, 2026. Accessed September 11, 2026.